KEYTRUDA® (pembrolizumab) KEYNOTE-522 clinical data presentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Access the KEYNOTE-522 clinical data presentation above to find out more about the trial’s primary analyses and 60-month follow-up data.

Click on the resource to download.

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.¹

Please refer to the SmPC for further information before making any prescribing decisions.

For more information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC), click on the product page button below:

Reference

1. KEYTRUDA Summary of Product Characteristics

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website